A federal advisory committee voted over two days on Thursday and Friday to recommend adding six peptides to an approved compounding list, a move that could open a narrow regulated path for specialty pharmacies if the FDA signs off. The panel rejected a seventh peptide, emideltide.
The recommendation covered BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. The vote was non-binding, and the FDA still has to decide whether to accept it, but the decision immediately put peptides back in focus for doctors, patients and online buyers who have been turning to them outside the regular drug system.
That attention matters because peptides are strings of amino acids smaller than a protein, and the category already includes FDA-approved medicines such as insulin and GLP-1s. Other peptides have surged in popularity online without robust data, creating the kind of gray area the committee said it was trying to narrow. If the FDA approves the recommendation, specially licensed compounding pharmacies that make customized medications would be able to use those ingredients under a regulated path. That would not make the products supplements anyone can buy off a store shelf, and it would not mean the agency has declared them safe or effective.
The vote also laid bare a sharp split inside the process. FDA staff scientists unanimously opposed adding every peptide to the list, warning about weak evidence, inconsistent recipes and possible harmful immune reactions. Even so, committee members who supported the move said they were trying to reduce harm by steering consumers away from a booming online black market run by overseas sellers of unregulated research chemicals. Six of the eight recently appointed committee members run clinics that offer peptides, a fact that sharpened scrutiny of how the panel weighed risk and access.
Dr. Haleem Mohammed, one of the members who voted yes, framed the issue as a choice between a tightly controlled path and a market that already exists outside it. “As a physician, I have to make sure that I'm keeping patients as safe as possible,” he said. “So, when I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? That's what I lose sleep at night over.”
Dr. Adriane Fugh-Berman, who opposed the recommendation, argued that popularity alone should not drive legalization. “Would the government endorse manufacturing heroin because it's cleaner than what is sold on the street?” she asked. “Just because a market is large doesn't mean that a product should be legalized. It means that a product should be studied.” The committee also rejected emideltide after reviewing evidence that included a single patient case report for narcolepsy and two small, uncontrolled studies for opioid withdrawal.
The next move belongs to the FDA, and that decision is the one that matters now. The committee’s vote gives the agency cover to act, but not a mandate, and it leaves one question hanging over the whole debate: whether the FDA will side with its staff scientists’ caution or decide that limiting the black market is the better way to reduce harm.
